{"id":"NCT03529942","sponsor":"Pacira Pharmaceuticals, Inc","briefTitle":"Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee","officialTitle":"An Open-Label Study to Evaluate the Effect of the Administration of FX006 on Synovial Inflammation in Patients With Osteoarthritis of the Knee","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-04-24","primaryCompletion":"2019-11-08","completion":"2020-03-09","firstPosted":"2018-05-18","resultsPosted":"2020-12-08","lastUpdate":"2024-01-24"},"enrollment":129,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis, Knee"],"interventions":[{"type":"DRUG","name":"FX006 32 mg","otherNames":["Zilretta"]}],"arms":[{"label":"FX006 32 mg","type":"EXPERIMENTAL"}],"summary":"This is an open-label study assessing the effect of the administration of a single intra-articular (IA) injection of FX006 32 mg on synovial volume in patients with osteoarthritis (OA) of the knee.","primaryOutcome":{"measure":"Mean Standardized Change in Synovial Volume (SV) at 6 Weeks","timeFrame":"Baseline to Week 6","effectByArm":[{"arm":"Total Population","deltaMin":-0.67,"sd":null},{"arm":"Patients With Baseline Synovitis","deltaMin":-0.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":14},"locations":{"siteCount":10,"countries":["United States","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":129},"commonTop":["Arthralgia","Oedema Peripheral","Upper Respiratory Tract Infection","Back Pain","Dizziness"]}}